|
|
Registry of Lobbyists - Jeffrey Malawski
To find further information on a company or organization check the Registry of Joint Stock Companies
|
|
Registration Number | Status | | 2053 | Terminated | | Initial registration date | Last date of any changes | 1-December-2020 | 22-July-2021 |
|
Lobbyist's Last Name Malawski |
Lobbyist's First Name Jeffrey |
Middle Initial |
|
Business Address of Lobbyist 16750 Trans Canada Highway |
City Kirkland |
Province/State PQ |
Country CA |
Postal/Zip Code H9H 4M7 |
Telephone (514) 214-3597 |
Fax (514) 428-4955 |
|
Business or Firm Name for Lobbyist (if applicable) Merck Canada Inc. |
Registry of Joint Stock Companies Number 3278688 |
Business Address of Lobbyist's Business or Firm 16750 Trans Canada Highway |
City Kirkland |
Province/State PQ |
Country CA |
Postal/Zip Code H9H 4M7 |
Telephone (514) 428-7920 |
Fax (514) 428-4955 |
|
Beneficiary Name |
Beneficiary Type |
|
Merck Frosst Company / Compagnie Merck Frosst |
Parent Company |
View
|
|
|
|
Description of Employer's Business: For over a century. Merck has been working to help the world be well. Merck is a global health care leader with a diversified portfolio of prescription medicines, vaccines, biologic therapies, including biosimilars, and animal health products. In Canada, Merck is a leader in a broad range of areas such as oncology, infectious diseases, diabetes, and vaccines, and markets more than 250 pharmaceutical and animal health products.
Based in Montreal, Quebec, Merck employs approximately 810 people across Canada. Merck is one of the top R&D investors in Canada, with investments totaling $25.1 million in 2015 and more than $1 billion since 2000. For more information about our operations in Canada, visit www.merck.ca and connect with us on YouTube and Twitter @MerckCanada. |
|
|
|
Description |
|
Focus of lobbying efforts will be on representations relating to the conditions under which innovative drugs and vaccines are marketed and reimbursed in Nova Scotia, including under the Nova Scotia Pharmacare Programs and the Nova Scotia Drug Formulary or under federal legislation. More specifically, representations are made to support a favourable and knowledgeable environment to implement new or improve current immunizations programs, the integrations of biosimilar drugs into the Nova Scotia Pharmacare Programs and the Nova Scotia Drug Formulary and to emphasize the importance that the federal and provincial governments respect their respective jurisdiction with respect to the approval, marketing and reimbursement of drugs. Merck Canada’s objective is to preserve a regulatory framework which creates a favourable business environment for the development of the life science sector, including innovative drugs, biosimilar drugs and vaccines, which are the company’s main sectors of activities. |
View
|
|
|
|
No funding from any government or agency
|
No private funding related to lobbying activities
|
|
|
|